Acumen Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $68.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $34.00K, a 9.68% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $34.00K, a 13.33% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $33.00K, a 10.00% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $32.00K, a 10.34% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $126.00K, a 9.57% increase from fiscal 2024.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $115.00K, a 6.50% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $123.00K, a 10.22% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $137.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $68.00K 10-Q · filed 2026-08-12 | $101.00K derived: sum of 3 quarters · filed 2026-08-12 | $133.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $34.00K 10-Q · filed 2026-05-12 | $67.00K derived: sum of 2 quarters · filed 2026-05-12 | $99.00K derived: sum of 3 quarters · filed 2026-05-12 | $130.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $65.00K derived: sum of 2 quarters · filed 2026-03-26 | $96.00K derived: sum of 3 quarters · filed 2026-08-12 | $126.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $63.00K derived: sum of 2 quarters · filed 2026-08-12 | $93.00K 10-Q · filed 2025-11-12 | $123.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $61.00K 10-Q · filed 2026-08-12 | $91.00K derived: sum of 3 quarters · filed 2026-08-12 | $120.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $30.00K 10-Q · filed 2026-05-12 | $60.00K derived: sum of 2 quarters · filed 2026-05-12 | $89.00K derived: sum of 3 quarters · filed 2026-05-12 | $117.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $59.00K derived: sum of 2 quarters · filed 2026-03-26 | $87.00K derived: sum of 3 quarters · filed 2026-03-26 | $115.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $57.00K derived: sum of 2 quarters · filed 2025-11-12 | $85.00K 10-Q · filed 2025-11-12 | $105.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $56.00K 10-Q · filed 2025-08-12 | $76.00K derived: sum of 3 quarters · filed 2025-08-12 | $103.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $28.00K 10-Q · filed 2025-05-13 | $48.00K derived: sum of 2 quarters · filed 2025-05-13 | $75.00K derived: sum of 3 quarters · filed 2025-05-13 | $113.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $47.00K derived: sum of 2 quarters · filed 2025-03-27 | $85.00K derived: sum of 3 quarters · filed 2025-03-27 | $123.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $65.00K derived: sum of 2 quarters · filed 2024-11-12 | $103.00K 10-Q · filed 2024-11-12 | $140.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $76.00K 10-Q · filed 2024-08-13 | $113.00K derived: sum of 3 quarters · filed 2024-08-13 | $147.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $38.00K 10-Q · filed 2024-05-14 | $75.00K derived: sum of 2 quarters · filed 2024-05-14 | $109.00K derived: sum of 3 quarters · filed 2024-05-14 | $142.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $71.00K derived: sum of 2 quarters · filed 2024-03-26 | $104.00K derived: sum of 3 quarters · filed 2024-03-26 | $137.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $67.00K derived: sum of 2 quarters · filed 2023-11-13 | $100.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $66.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |